Lumos Pharma, Inc. (LUMO) Misses Q4 EPS by 278c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q4 EPS of ($3.71), $2.78 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $114.33 thousand.

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• C3.ai (AI) Tops Q4 EPS by 5c, Beats on Revenue; Offers FY27 Revenue Guidance
• Petco Health and Wellness (WOOF) Misses Q1 EPS by 6c